Upregulation	0	12	O
of	13	15	O
vascular	16	24	B-Gene_or_gene_product
endothelial	25	36	I-Gene_or_gene_product
growth	37	43	I-Gene_or_gene_product
factor	44	50	I-Gene_or_gene_product
receptors	51	60	I-Gene_or_gene_product
is	61	63	O
associated	64	74	O
with	75	79	O
advanced	80	88	O
neuroblastoma	89	102	O
.	102	103	O

BACKGROUND	105	115	O
:	115	116	O
Angiogenesis	117	129	O
is	130	132	O
essential	133	142	O
for	143	146	O
tumor	147	152	B-Pathological_formation
growth	153	159	O
and	160	163	O
relies	164	170	O
on	171	173	O
the	174	177	O
production	178	188	O
of	189	191	O
angiogenic	192	202	O
factors	203	210	O
.	210	211	O

Vascular	212	220	B-Gene_or_gene_product
endothelial	221	232	I-Gene_or_gene_product
growth	233	239	I-Gene_or_gene_product
factor	240	246	I-Gene_or_gene_product
(	247	248	O
VEGF	248	252	B-Gene_or_gene_product
)	252	253	O
is	254	256	O
a	257	258	O
major	259	264	O
regulator	265	274	O
of	275	277	O
angiogenesis	278	290	O
that	291	295	O
binds	296	301	O
to	302	304	O
tyrosine	305	313	O
kinase	314	320	O
receptors	321	330	O
Flt	331	334	B-Gene_or_gene_product
-	334	335	I-Gene_or_gene_product
1	335	336	I-Gene_or_gene_product
and	337	340	O
KDR	341	344	B-Gene_or_gene_product
.	344	345	O

The	346	349	O
interaction	350	361	O
of	362	364	O
VEGF	365	369	B-Gene_or_gene_product
and	370	373	O
its	374	377	O
receptors	378	387	O
at	388	390	O
gene	391	395	O
and	396	399	O
protein	400	407	O
levels	408	414	O
in	415	417	O
neuroblastoma	418	431	B-Pathological_formation
remains	432	439	O
widely	440	446	O
unknown	447	454	O
.	454	455	O

METHODS	456	463	O
:	463	464	O
Tumor	465	470	B-Multi-tissue_structure
biopsy	471	477	I-Multi-tissue_structure
specimens	478	487	I-Multi-tissue_structure
and	488	491	O
serum	492	497	B-Organism_substance
were	498	502	O
obtained	503	511	O
from	512	516	O
37	517	519	O
neuroblastoma	520	533	B-Pathological_formation
patients	534	542	B-Organism
;	542	543	O
adrenal	544	551	B-Multi-tissue_structure
biopsy	552	558	I-Multi-tissue_structure
sections	559	567	I-Multi-tissue_structure
and	568	571	O
sera	572	576	B-Organism_substance
of	577	579	O
7	580	581	O
normal	582	588	O
children	589	597	B-Organism
served	598	604	O
as	605	607	O
controls	608	616	O
.	616	617	O

Biopsy	618	624	B-Multi-tissue_structure
specimens	625	634	I-Multi-tissue_structure
were	635	639	O
examined	640	648	O
by	649	651	O
real	652	656	O
-	656	657	O
time	657	661	O
reverse	662	669	O
transcription	670	683	O
polymerase	684	694	O
chain	695	700	O
reaction	701	709	O
(	710	711	O
RT	711	713	O
-	713	714	O
PCR	714	717	O
)	717	718	O
and	719	722	O
Western	723	730	O
blotting	731	739	O
;	739	740	O
serum	741	746	B-Organism_substance
was	747	750	O
analyzed	751	759	O
by	760	762	O
enzyme	763	769	O
-	769	770	O
linked	770	776	O
immunosorbent	777	790	O
assay	791	796	O
(	797	798	O
ELISA	798	803	O
)	803	804	O
.	804	805	O

VEGF	806	810	B-Gene_or_gene_product
-	810	811	I-Gene_or_gene_product
A	811	812	I-Gene_or_gene_product
(	812	813	I-Gene_or_gene_product
165	813	816	I-Gene_or_gene_product
)	816	817	I-Gene_or_gene_product
,	817	818	O
B	819	820	B-Gene_or_gene_product
,	820	821	O
C	822	823	B-Gene_or_gene_product
,	823	824	O
Flt	825	828	B-Gene_or_gene_product
-	828	829	I-Gene_or_gene_product
1	829	830	I-Gene_or_gene_product
,	830	831	O
and	832	835	O
KDR	836	839	B-Gene_or_gene_product
were	840	844	O
analyzed	845	853	O
.	853	854	O

RESULTS	855	862	O
:	862	863	O
VEGF	864	868	B-Gene_or_gene_product
isoforms	869	877	O
and	878	881	O
its	882	885	O
receptors	886	895	O
'	895	896	O
mRNA	897	901	O
were	902	906	O
expressed	907	916	O
in	917	919	O
neuroblastoma	920	933	B-Pathological_formation
and	934	937	O
control	938	945	O
tissues	946	953	B-Tissue
.	953	954	O

Whereas	955	962	O
the	963	966	O
ligands	967	974	O
were	975	979	O
increased	980	989	O
in	990	992	O
stages	993	999	O
III	1000	1003	O
and	1004	1007	O
IV	1008	1010	O
,	1010	1011	O
the	1012	1015	O
receptors	1016	1025	O
were	1026	1030	O
upregulated	1031	1042	O
in	1043	1045	O
stage	1046	1051	O
III	1052	1055	O
only	1056	1060	O
.	1060	1061	O

At	1062	1064	O
protein	1065	1072	O
level	1073	1078	O
,	1078	1079	O
VEGF	1080	1084	B-Gene_or_gene_product
-	1084	1085	I-Gene_or_gene_product
B	1085	1086	I-Gene_or_gene_product
and	1087	1090	O
C	1091	1092	B-Gene_or_gene_product
,	1092	1093	O
Flt	1094	1097	B-Gene_or_gene_product
-	1097	1098	I-Gene_or_gene_product
1	1098	1099	I-Gene_or_gene_product
,	1099	1100	O
and	1101	1104	O
KDR	1105	1108	B-Gene_or_gene_product
were	1109	1113	O
not	1114	1117	O
detectable	1118	1128	O
in	1129	1131	O
tissue	1132	1138	B-Organism_substance
lysates	1139	1146	I-Organism_substance
,	1146	1147	O
whereas	1148	1155	O
VEGF	1156	1160	B-Gene_or_gene_product
-	1160	1161	I-Gene_or_gene_product
A	1161	1162	I-Gene_or_gene_product
was	1163	1166	O
increased	1167	1176	O
in	1177	1179	O
stages	1180	1186	O
III	1187	1190	O
and	1191	1194	O
IV	1195	1197	O
.	1197	1198	O

Serum	1199	1204	B-Organism_substance
VEGF	1205	1209	B-Gene_or_gene_product
protein	1210	1217	O
levels	1218	1224	O
were	1225	1229	O
upregulated	1230	1241	O
in	1242	1244	O
stage	1245	1250	O
III	1251	1254	O
.	1254	1255	O

CONCLUSIONS	1256	1267	O
:	1267	1268	O
VEGF	1269	1273	B-Gene_or_gene_product
-	1273	1274	I-Gene_or_gene_product
A	1274	1275	I-Gene_or_gene_product
(	1275	1276	I-Gene_or_gene_product
165	1276	1279	I-Gene_or_gene_product
)	1279	1280	I-Gene_or_gene_product
is	1281	1283	O
one	1284	1287	O
of	1288	1290	O
the	1291	1294	O
major	1295	1300	O
angiogenesis	1301	1313	O
regulators	1314	1324	O
among	1325	1330	O
the	1331	1334	O
ligands	1335	1342	O
'	1342	1343	O
family	1344	1350	O
of	1351	1353	O
VEGF	1354	1358	B-Gene_or_gene_product
,	1358	1359	O
whereas	1360	1367	O
its	1368	1371	O
receptors	1372	1381	O
KDR	1382	1385	B-Gene_or_gene_product
,	1385	1386	O
and	1387	1390	O
most	1391	1395	O
probably	1396	1404	O
Flt	1405	1408	B-Gene_or_gene_product
-	1408	1409	I-Gene_or_gene_product
1	1409	1410	I-Gene_or_gene_product
,	1410	1411	O
may	1412	1415	O
contribute	1416	1426	O
to	1427	1429	O
a	1430	1431	O
poor	1432	1436	O
prognosis	1437	1446	O
(	1447	1448	O
angiogenic	1448	1458	O
)	1458	1459	O
phenotype	1460	1469	O
,	1469	1470	O
as	1471	1473	O
indicated	1474	1483	O
by	1484	1486	O
their	1487	1492	O
upregulated	1493	1504	O
MRNA	1505	1509	O
levels	1510	1516	O
in	1517	1519	O
stage	1520	1525	B-Pathological_formation
III	1526	1529	I-Pathological_formation
neuroblastoma	1530	1543	I-Pathological_formation
.	1543	1544	O

VEGF	1545	1549	B-Gene_or_gene_product
-	1549	1550	I-Gene_or_gene_product
A	1550	1551	I-Gene_or_gene_product
(	1551	1552	I-Gene_or_gene_product
165	1552	1555	I-Gene_or_gene_product
)	1555	1556	I-Gene_or_gene_product
mainly	1557	1563	O
contributes	1564	1575	O
to	1576	1578	O
increased	1579	1588	O
serum	1589	1594	B-Organism_substance
VEGF	1595	1599	B-Gene_or_gene_product
levels	1600	1606	O
and	1607	1610	O
may	1611	1614	O
serve	1615	1620	O
as	1621	1623	O
a	1624	1625	O
diagnostic	1626	1636	O
tool	1637	1641	O
in	1642	1644	O
advanced	1645	1653	O
-	1653	1654	O
stage	1654	1659	O
neuroblastoma	1660	1673	O
.	1673	1674	O

